High-Level Summary
Core Findings
The transition from a compensated right ventricle (cRV) to a decompensated right ventricle (dRV) in pulmonary arterial hypertension (PAH) is driven primarily by the phenotypic shift of cardiac fibroblasts (cFBs) into cardiac myofibroblasts (cMFBs), rather than primary cardiomyocyte (CM) failure.
Biomarker Potential
Loss of uncoupling protein 2 (UCP2) in the RV, often triggered by inflammation (TNF-alpha) or a specific loss-of-function single nucleotide polymorphism (SNP; rs659366), serves as a critical predictor for early RV decompensation regardless of pulmonary artery pressure levels.
Background: The Right Ventricle as the Determinant of Survival
In the clinical management of pulmonary arterial hypertension (PAH), the focus has traditionally centered on the pulmonary vasculature. However, it is the right ventricle (RV) that ultimately dictates patient prognosis. While some patients maintain a compensated RV (cRV) state for years despite high afterload, others rapidly progress to decompensated RV (dRV) failure. The molecular ‘switch’ that triggers this transition has remained elusive, complicating efforts to risk-stratify patients and develop RV-targeted therapies.
Recent evidence suggests that the myocardial response to pressure overload is not uniform. The traditional view of RV failure often emphasizes cardiomyocyte exhaustion; however, the role of the cardiac stroma—specifically the fibroblast population—is increasingly recognized as a pivot point in structural remodeling. This study investigates the contribution of cardiac myofibroblasts (cMFBs) and the mitochondrial protein UCP2 in this critical transition.
Study Design and Methodology
To unravel the complexities of RV failure, researchers utilized a multi-modal approach combining animal models and human clinical cohorts.
Experimental Models
Two distinct rat models of RV stress were employed: the monocrotaline (MCT) model, which induces significant inflammation alongside pulmonary hypertension, and the pulmonary artery banding (PAB) model, which provides a purely mechanical, less inflammatory afterload. These models allowed for a comparison between rapid, inflammation-driven decompensation and slow, mechanically-driven progression.
Clinical Cohorts
The study analyzed three patient cohorts totaling 81 individuals, comparing those with PAH (Group 1) to those with Group 2 pulmonary hypertension (PHT-2). The investigators utilized echocardiography and right heart catheterization to classify patients into cRV and dRV groups, subsequently analyzing RV tissue samples for cellular and genetic markers.
Cellular and Molecular Analysis
The research team focused on the role of uncoupling protein 2 (UCP2), a mitochondrial inner-membrane protein known to regulate mitochondrial calcium (mCa++) and metabolic signaling. They investigated how UCP2 levels influence the differentiation of cFBs into cMFBs and examined the impact of the UCP2 SNP rs659366 on human RV performance.
Key Findings: The Myofibroblast Transformation
A Non-Cardiomyocyte Driver of Failure
One of the most striking findings was that in isolated MCT dRV hearts, contractility was significantly reduced at the organ level, but isolated cardiomyocytes (CMs) from these same hearts did not show the same degree of functional impairment. This suggests that the primary driver of RV pump failure resides in the non-myocyte compartment—specifically the fibrotic and structural changes mediated by cMFBs.
The UCP2-mCa++ Axis
The researchers observed a significant increase in cMFB populations in MCT-induced dRV, but not in the more stable PAB-induced RV. At the molecular level, mitochondrial respiration was severely impaired in dRV cMFBs compared to control cFBs. Interestingly, while mitochondrial respiration decreased in the fibroblasts, it actually increased in the cardiomyocytes of the same hearts, highlighting a cell-specific metabolic divergence.
The study identified a progressive loss of UCP2 and mitochondrial calcium (mCa++) in cMFBs as the RV transitioned from compensated to decompensated. UCP2 appears to be essential for maintaining fibroblast homeostasis; its loss triggers the transformation into the more aggressive, pro-fibrotic myofibroblast phenotype.
Inflammation and UCP2 Suppression
Inflammatory signaling, specifically via Tumor Necrosis Factor alpha (TNF-alpha), was found to selectively decrease UCP2 mRNA and protein levels in RV fibroblasts but not in RV cardiomyocytes. This explains why the MCT model (highly inflammatory) leads to faster decompensation than the PAB model (mechanical stress only), and why systemic inflammation in PAH patients is so detrimental to RV function.
Human Evidence and Genetic Predisposition
The clinical relevance of these findings was confirmed in human PAH patients. Those with dRV exhibited significantly higher levels of cMFBs and lower UCP2 expression compared to those with cRV. Crucially, this relationship was specific to PAH and was not observed in PHT-2 patients, suggesting a unique pathobiology in Group 1 pulmonary hypertension.
Furthermore, the UCP2 loss-of-function SNP (rs659366) was strongly associated with worse RV performance. Patients carrying this genetic variant demonstrated lower tricuspid annular plane systolic excursion (TAPSE) and lower cardiac indices. Most notably, this genetic predisposition predicted RV failure even when patients had similar mean pulmonary arterial pressures, suggesting that the rs659366 SNP makes the RV inherently more vulnerable to afterload-induced failure.
Expert Commentary: Shifting the Paradigm
This research represents a significant shift in our understanding of RV failure. For decades, the RV was seen as a passive victim of the pulmonary vasculature. By identifying the UCP2-cMFB axis, this study positions the RV fibroblast as an active, genetically-regulated participant in the failure process. The observation that isolated CMs maintain function while the whole heart fails underscores the importance of the extracellular matrix and the cellular ‘milieu’ in RV mechanics.
However, some limitations must be considered. While the MCT and PAB models are standard, they do not perfectly replicate the chronicity of human PAH. Additionally, while the correlation between rs659366 and RV dysfunction is robust, prospective longitudinal studies are required to determine if genetic screening for this SNP can alter clinical outcomes through earlier intervention.
Conclusion
The transition from compensation to failure in the right ventricle is a cell-specific process driven by the loss of UCP2 and the subsequent emergence of cardiac myofibroblasts. This transformation is accelerated by inflammation and genetically programmed by the rs659366 SNP. These findings provide a new framework for identifying at-risk patients and suggest that targeting the UCP2 pathway or the fibroblast-to-myofibroblast transition could offer a novel therapeutic avenue to prevent RV decompensation in PAH.
References
1. Zhang Y, Bonnet S, Provencher S, et al. A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension. Circulation. 2026. PMID: 41797703.
2. Vonk Noordegraaf A, Westerhof BE, Westerhof N. The Relationship Between the Right Ventricle and its Afterload in Pulmonary Hypertension. J Am Coll Cardiol. 2017;69(2):236-243.
3. Toba A, Alzoubi A, O’Neill K, et al. Mitochondrial calcium as a target in right ventricular failure. Am J Respir Crit Care Med. 2021;203:A1024.
